https://synapse.patsnap.com/blog/biologics-sequence-review-report-modotuximab-2026-mcp
Modotuximab Biologics Sequence Review Report 2026: EGFR Similarity and Patent-Risk Signals
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Modotuximab, an antibody targeting EGFR.
risk signalsmodotuximabbiologicssequencereview